MedTrace Logo

Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications

NCT02213887 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-10-08

No results posted yet for this study

Summary

The purpose of this 9-day study is to determine if:

1. Pantoprazole modifies the steady-state plasma concentrations of orally administered psychotropic medications including valproic acid, lithium, and second-generation antipsychotics (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)
2. Serum gastrin levels change within a week of starting or stopping pantoprazole

Conditions

  • Psychotic Disorders
  • Gastroesophageal Reflux

Interventions

DRUG

Pantoprazole

40 mg PO QAM

DRUG

Pantoprazole

0 mg PO QAM

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Ric M. Procyshyn, Ph.D · University of British Columbia

  • Alasdair Barr, Ph.D · University of British Columbia

  • William Honer, MD · University of British Columbia

  • Randall White, MD · University of British Columbia

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2020-11-02
Completion
2020-11-02

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02213887 on ClinicalTrials.gov